ADMA
Another day, another ADMA legal cloud
ADMA Biologics is back in the legal spotlight, and not in the fun, “new drug approval” kind of way. Scott+Scott Attorneys at Law says it has launched an investigation into whether certain ADMA directors and officers mishandled the company and breached their fiduciary duties.
The firm says it’s looking at whether ADMA and its shareholders were damaged. That’s attorney-speak for: was management doing the corporate equivalent of driving with one hand on the wheel and the other checking email?
Why investors should care
This isn’t a sales pitch for a product or a clean earnings beat. It’s another sign that ADMA is dealing with a thickening legal thicket. When shareholder lawsuits and investigations start stacking up, they can:
- add distraction for management
- raise legal and settlement costs
- keep a lid on sentiment, even if the underlying business is fine
The bigger picture
The headline also nods to Culper Research, which is part of the backstory here, suggesting this legal mess has been brewing for a while. So while this may not be the kind of event that changes next quarter’s revenue by itself, it absolutely can shape how investors think about governance risk.
Big picture: when the plaintiff-lawyer carousel keeps spinning, the stock usually doesn’t get a relaxing afternoon.